First patient dosed in Amarantus Bio's mid-stage study of eltoprazine in movement disorder

• Amarantus BioScience (OTCPK:AMBS) announces that the first patient has been dosed in its Phase 2b clinical trial assessing its lead product candidate, eltoprazine, for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). Top-line results from the 60-subject, randomized, double-blind study are expected in H1 2016.  The estimated completion date of the study is December 2016.
• Eltoprazine, a small molecule neuromodulator, is a 5HT 1A/1B receptor agonist under development for PD-LID and adult attention deficit hyperactivity disorder (ADHD).
• PD-LID is an involuntary movement disorder that results from prolonged levodopa-based therapy, the standard-of-care for patients with Parkinson's disease. PD-LID occurs in as many as 80% of PD patients. It is difficult to treat and prevents patients from performing routine daily tasks.